FDA may use blockchain to review product recalls

The FDA may begin using blockchain systems to help drug and medical products reviews and recalls, according to CoinDesk.

Advertisement

Amy Abernethy, MD, the FDA principal deputy commissioner, said the administration is seeking to modernize the way healthcare providers, drug manufacturers and regulatory agencies communicate. She made the announcement Aug. 22 at the Office of the National Coordinator for Health IT Third Interoperability Forum.

Although details were sparse, Dr. Abernethy said the FDA plans to roll out artificial intelligence, application programing interfaces and blockchain.

“I want FDA to get our own technical house in order so that tech can ‘snap in’ — we can be agile and efficient. We need to be able to have common interfaces with industry so we can pass data between our organizations, have collaborative review, etc.,” Dr. Abernethy said.

More articles on supply chain:
VA, Defense Department to partner on supply-ordering to cut waste, fraud
How US-China trade tensions are affecting the medical device industry
AmerisourceBergen to close California distribution center, cut 100 jobs

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

Beyond the bottleneck: How health systems are improving access, flow and care continuity

Thursday, July 30
1:00 PM - 2:00 PM CDT

Presenters: Imamu Tomlinson, MD, MBA, VituityWilliam Morice II, MD, PhD, Mayo Clinic LaboratoriesJordan Dale, MD, Houston MethodistAsh Tengshe, City of HopeChris Klay, MHA, MA, PT, FACHE, Hospital Sisters Health System

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.